• First quarter 2026 revenue expected to be $2.7 million, impacted by memory inventory and supply chain delays
• Blaize maintains full year 2026 revenue guidance of $130.0 million
• New NeoTensr contract expected to generate up to $50.0 million in revenue

EL DORADO HILLS, Calif., April 14, 2026 /PRNewswire/ — Blaize Holdings, Inc. (Nasdaq: BZAI, Nasdaq: BZAIW) (“Blaize,” the “Company,” “we,” “our,” or “us”), a leader in programmable, energy-efficient AI computing, announced today expected revenue for the first fiscal quarter ending March 31, 2026, and a newly awarded contract with NeoTensr, a system integrator and software company, expected to generate $50.0 million in revenue, following last week’s previously announced launch of Blaize AI Services.

Preliminary First Quarter Revenue

Expected revenue for the first quarter of 2026 was approximately $2.7 million. Results were primarily impacted by temporary supply chain constraints that affected shipment timing, despite solid underlying customer demand.

“The global memory shortage reduced server purchase availability from our primary supplier in the first quarter of 2026, which prevented us from fulfilling customer demand,” said Harminder Sehmi, CFO of Blaize. “We have secured the inventory needed to deliver $10.0 – $12.0 million to our customer in late April and May, and we remain on track with our full year 2026 revenue guidance.”  

Business Updates

Blaize also announced today that it has entered into a new contract with NeoTensr for up to $50.0 million in revenue within the first year of the agreement, with fulfillment expected to begin in the second quarter. This is in addition to over $20.0 million in revenue that Blaize recognized from a NeoTensr order in the fourth quarter of 2025.

“Our agreement covers hybrid systems across edge and enterprise data center environments,” said Dinakar Munagala, Co-Founder and CEO of Blaize. “NeoTensr is building a multi-phased data center infrastructure across Asia Pacific, validating our Hybrid AI architecture, scaling into multi-city edge inference deployments, and incorporating the full Blaize AI Services stack. We expect each stage to drive progressively higher-margin revenue.”

“We chose Blaize because their Hybrid AI platform gives us the foundation to build and monetize AI infrastructure at scale across the Asia Pacific region,” said Liang Wang, CEO of NeoTensr. “From edge inference to full AI Services deployment, this partnership positions NeoTensr to capture a significant share of the growing demand for efficient, production-ready AI across our markets, and we are just getting started.”

Last week at GITEX Asia, Blaize announced the launch of Blaize AI Services to transform AI infrastructure into production-ready APIs. The new platform is designed to help cloud providers, data center operators, system integrators, and enterprises deploy application-level AI services faster, reduce cost per query, and create recurring AI service revenue. 

“We continue to meet the demand for sector innovation, as evidenced by the significant interest from cloud service providers and data center operators with our recent launch of Blaize AI Services,” said Dinakar Munagala, Co-Founder and CEO of Blaize. “Blaize AI Services is differentiated by the delivery of quicker and highly efficient deployment of application-level AI services, which we believe represents repeat monetization.”

About Blaize

Blaize delivers a programmable AI platform, purpose-built for AI inference workloads in real-world environments. Its Hybrid AI architecture combines the Blaize GSP (Graph Streaming Processor), an efficient AI processor, with GPU-based infrastructure, enabling AI inference workloads to run across edge, cloud, and data center. Blaize solutions support computer vision, multimodal AI, and sensor-driven applications across smart cities, industrial automation, telecommunications, retail, logistics, and defense. Blaize is headquartered in El Dorado Hills, California, with a global presence across North America, Europe, the Middle East, and Asia. To learn more, visit www.blaize.com or follow us on LinkedIn @blaizeinc.

About NeoTensr

NeoTensr is a technology company specializing in hardware and software system development for edge, enterprise and data center environments. For more information, visit www.neotensr.com.

Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are based on beliefs and assumptions and on information currently available to Blaize, including expectations and scope of customer contracts, including potential values and the timing of revenues pursuant to such contracts; preliminary estimates of results of operations and guidance on results for future periods; what the AI Services offering will achieve; the industry in which Blaize operates, market opportunities, and product offerings. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to those factors discussed under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 24, 2026, and other documents filed by Blaize from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Blaize assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law, including the securities laws of the United States and the rules and regulations of the SEC. Blaize does not give any assurance that it will achieve its expectations. The expected revenue for the first fiscal quarter ended March 31, 2026 is preliminary as Blaize has not completed its financial statements for the quarter.

Promotions reflect commitment to expertise, collaboration, and client service excellence. 

NEW YORK, April 14, 2026 /PRNewswire/ — Global consulting firm J.S. Held announces the promotion of hundreds of team members across multiple geographies and areas of expertise, recognizing their achievements and contributions to the firm’s continued growth and client impact. These promotions reflect the firm’s commitment to fostering a culture that values and recognizes specialized knowledge, collaboration, and innovation as it continues to deliver exceptional service and strategic insight to organizations in large and emerging markets.

Executive Perspective

Chief Executive Officer Lee Spirer acknowledges, “J.S. Held was founded on the principle of being a trusted advisor, known for objective and insightful perspectives and ensuring clients are in a position to make well-informed decisions.”  Lee continues, “Today, that founding principle thrives in the hundreds of team members we are proud to promote, each demonstrating the talent, dedication, and integrity our clients rely on.”

Deep Expertise for High-Stakes Engagements

J.S. Held is trusted by clients around the world to respond in moments of crisis, delivering deep technical, scientific, and financial expertise when the stakes are highest.  Across the firm, teams are called upon to investigate failures, assess damage, quantify economic loss, and provide clarity in complex disputes, often in high-stakes legal and insurance settings where findings must withstand rigorous scrutiny.

The firm’s experts conduct technical and financial investigations that address not only physical damage but also the value and integrity of intangible assets, including artificial intelligence and data that enable client products and services. Whether responding to catastrophic events or resolving financial disputes, J.S. Held’s work is grounded in precision, credibility, and real-world impact.

This depth of experience in reactive engagements directly informs the firm’s ability to guide clients proactively. J.S. Held’s deep understanding of how and why things go wrong, along with the financial and operational consequences that follow, enables the firm to help organizations anticipate risk, improve governance, and build long-term resilience. Advisors draw on courtroom-tested insights to deliver forward-looking solutions that enhance performance, protect value, and support long-term business sustainability.

Industry Leadership

J.S. Held experts have been engaged in some of the largest, most complex mandates. More than 1500 experts serve as trusted advisors to organizations across six continents, working with:

• 84% of the Global 200 Law Firms
• 75% of the Forbes Top 20 Insurance Companies
• 90% of the NAIC Top 50 Property & Casualty Insurers
• 71% of Fortune 100 Companies

“From every corner of our business, agile, collaborative, creative, and client-centric teams provide solution-forward advisory to clients across the globe, no matter the scope or complexity of a project, which is reflective of the trusted advisor role we have earned over the last 50 years,” adds Lee. 

Investment in People and Culture

“The team members we recognize today exemplify our core values and are committed to seeking new and innovative ways to serve our clients and advance thought leadership in our industry,” shares Marjan Panah, J.S. Held Chief People Officer. Their promotions underscore J.S. Held’s strong belief that client service and employee engagement are synonymous, as the firm remains committed to providing a first-class work environment and cultivating a sense of community among its team. J.S. Held recognizes the importance of expert development at all levels within the organization as central to delivering the best solutions for clients.

About J.S. Held

J.S. Held is a global consulting firm that combines technical, scientific, financial, and strategic expertise to advise clients seeking to realize value and mitigate risk. Our professionals serve as trusted advisors to organizations facing high stakes matters demanding urgent attention, staunch integrity, proven experience, clear-cut analysis, and an understanding of both tangible and intangible assets. The firm provides a comprehensive suite of services, products, and data that enable clients to navigate complex, contentious, and often catastrophic situations.

J.S. Held, its affiliates and subsidiaries are not certified public accounting firm(s) and do not provide audit, attest, or any other public accounting services. J.S. Held is not a law firm and does not provide legal advice.  Securities offered through PM Securities, LLC, d/b/a Phoenix IB or Ocean Tomo Investments, a part of J.S. Held, member FINRA/SIPC.  All rights reserved.

Contact:

Kristi L. Stathis | Global Public Relations | +1 786 833 4864 | Kristi.Stathis@jsheld.com

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, April 14, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Kristen Scholer delivers the pre-market update on April 14th

• Equities are little changed Tuesday morning after the S&P 500 gained 1% yesterday and is clinging to optimism for a longer-term ceasefire in the Middle East.  
• OpenLoop Health CEO Dr. Jon Lensing will join NYSE Live this morning to discuss the company’s expansion into sleep diagnostics in partnership with Happy Sleep.
• Gold medalists Breezy Johnson and Kate Delson will deliver remarks, ring the Opening Bell, and speak to Kristen Scholer after markets open this morning.
• IonQ (NYSE: IONQ) Chairman and CEO Niccolo de Masi will celebrate World Quantum Day at the NYSE and join Taking Stock this afternoon.

Opening Bell
Olympic Gold Medalist Breezy Johnson and Paralympic Gold Medalist Kate Delson ring the Opening Bell

Closing Bell
IonQ (NYSE: IONQ) celebrates World Quantum Day

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App: TV.NYSE.com

Diversified Energy Company CEO Rusty Hutson, Jr. rang the bell.

SYDNEY, April 14, 2026 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Commercial Manufacturing Agreement for ⁶⁴Cu-SAR-bisPSMA with Nucleus RadioPharma, an innovative contract development and manufacturing organisation (CDMO) in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies.

The Agreement relates to Nucleus RadioPharma’s state-of-the-art facility in Rochester, Minnesota, which is capable of manufacturing around 50,000 patient doses per year, and future production in Spring House, Pennsylvania. The Spring House facility is a 47,000 square foot site that is planned to open in 2028, enabling broad coverage across the northeast of the US with up to 600,000 doses of ⁶⁴Cu-SAR-bisPSMA per year. Together, these two facilities in Minnesota and Pennsylvania will provide access to key commercial markets with manufacturing and distribution to all 50 states in the US and select international sites, including Europe.

The Commercial Manufacturing Agreement further builds on Clarity’s existing partnership with Nucleus RadioPharma with a Master Services Agreement and ⁶⁷Cu-SAR-bisPSMA Clinical Supply Agreement in place from November 2024¹, covering the existing site in Rochester with additional facilities in Pennsylvania² and future strategic sites to expand patient access.

This Agreement represents an important step in Clarity’s continued build out of its manufacturing capabilities ahead of ⁶⁴Cu-SAR-bisPSMA’s anticipated commercial launch upon successful completion of Phase III registrational trials with this product, AMPLIFY³ and CLARIFY⁴, and subsequent US Food and Drug Administration (FDA) New Drug Application (NDA) approval.

Geoffrey Johnson, MD, PhD, Chief Scientific Officer of Nucleus RadioPharma, commented, “Nucleus RadioPharma is excited to produce a next-generation diagnostic imaging agent, ⁶⁴Cu-SAR-bisPSMA, that data shows is capable of visualising tiny prostate cancer lesions that the current standard of care prostate specific membrane antigen (PSMA) positron emission tomography (PET) fails to detect. Earlier cancer detection and better cancer staging directly affects patient management and treatment outcomes and I firmly believe that seeing is saving. At Nucleus RadioPharma, we are proud to be driving demonstrable advances at the cutting edge of theranostics.”

Stephen Hahn, MD, Chief Executive Officer of Nucleus RadioPharma, commented, “We are pleased to continue growing our partnership with Clarity through this new Commercial Manufacturing Agreement. At Nucleus RadioPharma, we share Clarity’s goal of improving treatment outcomes for patients with cancer and look forward to delivering novel products to people in need of better diagnostic and therapeutic options. ⁶⁴Cu-SAR-bisPSMA is now quickly approaching its market launch, and with recently released data highlighting its detection benefits in comparison to standard of care PSMA PET, we could not be more excited about being part of the change in shaping the future of prostate cancer diagnostics.”

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, commented, “Clarity is building a strong foundation with its supply and manufacturing strategy to support a large-scale commercial rollout of ⁶⁴Cu-SAR-bisPSMA from day one, with capability to supply not only the entire existing PSMA PET market, but a larger pool of patients that could benefit from our optimised product, given the promising data we have seen in the clinic to date. With large-scale drug product manufacturing, reinforced by large-scale copper-64 production, we will be able to provide ⁶⁴Cu-SAR-bisPSMA on demand through centralised manufacturing and distribution, broadly with sites servicing the entirety of the US and beyond, including sites close to areas of high demand. The half-life of copper-64 gives us the freedom to deliver a number of models in order to meet the future demand for our products.

“Together with Clarity’s existing copper-64 supply agreements with SpectronRx, Nusano and Theragenics, as well as a ⁶⁴Cu-SAR-bisPSMA commercial manufacturing agreement with SpectronRx, the new Agreement with Nucleus RadioPharma further enhances Clarity’s broad network of high-volume production in distinct US geographies, building a tiered approach with regional distribution. The network is designed to support commercial-scale demand with secure, seamless and abundant supply and manufacturing.

“Nucleus RadioPharma is a trusted partner with extensive expertise in radiopharmaceuticals across not only the supply and manufacturing side, but also with a unique insight into the impact that radiopharmaceuticals can have on the healthcare system, treating clinicians and their patients. We look forward to continuing to work with their team as we continue to deliver on our promise of improving treatment outcomes for patients with cancer.”

The Commercial Manufacturing Supply Agreement is effective as of 14 April 2026. Cancellation and extension provisions are aligned with industry standard rates.

Disclaimer

⁶⁴Cu-SAR-bisPSMA and ⁶⁷Cu-SAR-bisPSMA are unregistered products. Their safety and efficacy have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

About Nucleus RadioPharma

Nucleus RadioPharma is an innovative CDMO in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies. With an emphasis on innovation and quality, the company provides an array of services, from formulation and analytical development to regulatory documentation and drug product manufacturing. Nucleus RadioPharma’s technology platforms are at the forefront of radiopharmaceutical research, designed to advance new therapies through clinical trials to commercialization. Recognized for its flexible approach, the company offers multiple onboarding points to accommodate innovators at various stages of their product lifecycle. Backed by Eclipse, Mayo Clinic, AstraZeneca, GE HealthCare, Echo Global, Fox Chase Cancer Center, Granger Management, Mercy Health, and University of Missouri, Nucleus RadioPharma stands well-supported by leading institutions and organizations committed to advancing healthcare through innovative solutions.
Please visit nucleusrad.com and follow on LinkedIn for more information.

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.
www.claritypharmaceuticals.com

References

1. Clarity Pharmaceuticals. Clarity and Nucleus RadioPharma sign Master Services Agreement and Cu-67 SAR-bisPSMA Clinical Supply Agreement. https://www.claritypharmaceuticals.com/news/nucleus/
2. Nucleus RadioPharma Expands Radiopharmaceutical Research, Development and Manufacturing Capacity, Addressing Nationwide Supply Chain Constraints, BusinessWire, 21 October 2024, https://www.businesswire.com/news/home/20241021820034/en/Nucleus-RadioPharma-Expands-Radiopharmaceutical-Research-Development-and-Manufacturing-Capacity-Addressing-Nationwide-Supply-Chain-Constraints
3. ClinicalTrials.gov Identifier: NCT06970847. https://clinicaltrials.gov/study/NCT06970847
4. ClinicalTrials.gov Identifier: NCT06056830. https://clinicaltrials.gov/study/NCT06056830

This announcement has been authorised for release by the Executive Chairperson.

New Powered by Apkudo technology for buff and polish combines advanced plasma treatment and precision automation to accelerate screen restoration at scale for global refurbishment leaders.

BALTIMORE, April 14, 2026 /PRNewswire/ — Apkudo, the Device Passport™ Platform company, today announced that Qates joined the Powered by Apkudo ecosystem, with the launch of the Apkudo Buff-Polish system. This industrial-grade screen restoration solution is designed for high-volume device processors, carriers, and original equipment manufacturers seeking to maximize the resale value of pre-owned assets. By integrating Qates’ specialized hardware with the Apkudo platform, customers unlock a scalable way to turn scratched screens into like-new, revenue-ready devices.

Qates Powered by Apkudo Buff-Polish Product Image

Cosmetic condition, particularly screen quality, is one of the strongest predictors of resale value in the secondary device market, with scratched displays often triggering double-digit price reductions or costly replacements. Traditional refurbishment often requires costly screen replacements or manual polishing processes that are difficult to scale and frequently lead to inconsistent quality and lower margins for high-volume operators. As consumer demand for pristine used devices increases, the industry needs a repeatable, data-driven method to restore screens without compromising device integrity.

The Qates system offers an easy-to-scale, automated solution that restores screens to a high-quality finish while protecting the device’s original display. This efficient process removes scratches more effectively than traditional methods without the mess or complicated setup usually required for restoration. Each system can handle 12 devices per hour, often enabling businesses to more than double their typical output with a small team. Unlike standalone cosmetic restoration tools, every Buff-Polish action is automatically recorded in the Apkudo Device Passport, creating a permanent, auditable record of improvement that travels with the device across owners, channels, and markets.

“As part of the Powered by Apkudo ecosystem, the Qates system connects physical restoration with digital verification, turning cosmetic improvements into durable, market-recognized value,” said Josh Matthews, CEO and Co-Founder of Apkudo. “This is not just about polishing glass; it is about using data and precision to unlock the full financial and circular potential of every asset.”

Strategic Benefits for Asset Owners

• Higher residual value: Eliminate scratches that directly reduce resale prices
• Lower refurbishment cost: Avoid unnecessary screen replacements
• Verified trust: Every improvement recorded in the Device Passport
• Operational scale: High throughput without expanding facility footprint
• Sustainable growth: Extend device lifespan and reduce parts dependency

Learn more about Apkudo’s Device Passport platform and the new Buff-Polish solution by visiting apkudo.com. 

About Apkudo
Apkudo is the Device Passport Platform for the connected device ecosystem. We capture and unify data from every program, transaction, and touchpoint across a device’s lifecycle, creating a single, trusted Device Passport™ for every asset. For companies that manage, sell, or buy devices, this means a verified record they can act on: to restore buyer confidence, maximize value, and reduce risk at every decision point. Our unique advantage is data fidelity and veracity, built on precision-automated robotics that have processed millions of devices, generating objective, machine-verified data that no competitor can match. To learn more, visit apkudo.com.

Media Contact:
Kristen Barry
SVP Marketing and Communications
kristen.barry@apkudo.com